Provided by Tiger Trade Technology Pte. Ltd.

Rezolute, Inc.

4.64
+0.26005.94%
Post-market: 4.57-0.0700-1.51%17:40 EDT
Volume:2.20M
Turnover:10.06M
Market Cap:446.80M
PE:-6.21
High:4.69
Open:4.33
Low:4.32
Close:4.38
52wk High:11.46
52wk Low:1.07
Shares:96.29M
Float Shares:72.51M
Volume Ratio:1.03
T/O Rate:3.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7467
EPS(LYR):-0.7467
ROE:-59.04%
ROA:-35.32%
PB:4.44
PE(LYR):-6.21

Loading ...

Rezolute - 6 of 8 Participants Meet Primary Endpoint Responder Criterion in Uplift Study

THOMSON REUTERS
·
Jun 02

Rezolute Announces Positive Interim Data for Its Phase 3 Uplift Study of Ersodetug in Tumor Hyperinsulinism

THOMSON REUTERS
·
Jun 02

Rezolute Is Maintained at Buy by Maxim Group

Dow Jones
·
May 15

Rezolute price target raised to $10 from $4 at Maxim

TIPRANKS
·
May 14

Maxim Group Keeps Their Buy Rating on Rezolute (RZLT)

TIPRANKS
·
May 14

High Growth Tech Stocks in US for May 2026

Simply Wall St.
·
May 14

Rezolute Q3 EPS $(0.16), Inline

Benzinga Earnings
·
May 13

Rezolute Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Rezolute Q3 net loss narrows as R&D expenses fall

Reuters
·
May 13

Rezolute Q3 FY26 net loss narrows to $16.2 million

Reuters
·
May 13

BRIEF-Rezolute Q3 EPS USD -0.16

Reuters
·
May 13

Press Release: Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Dow Jones
·
May 13

Rezolute management attends H.C. Wainwright BioConnect investor conference

Reuters
·
May 11

Rezolute Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
May 09

Rezolute publishes corporate presentation on ersodetug treatment for hyperinsulinism hypoglycemia

Reuters
·
May 02

Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026

TIPRANKS
·
May 02

Rezolute reports Phase 3 sunRIZE CGM data showing improved hypoglycemia control with ersodetug

Reuters
·
May 02

Rezolute Announces Oral Presentation of Results From Its Phase 3 Sunrize Study of Ersodetug in Patients With Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

THOMSON REUTERS
·
May 02

Rezolute to present Phase 3 sunRIZE ersodetug data in congenital hyperinsulinism at PES meeting

Reuters
·
Apr 21